These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 38300458)
21. Update on the management of relapsed/refractory chronic lymphocytic leukemia. Bennett R; Seymour JF Blood Cancer J; 2024 Feb; 14(1):33. PubMed ID: 38378673 [TBL] [Abstract][Full Text] [Related]
22. How We Manage Patients with Indolent B-Cell Malignancies on Bruton's Tyrosine Kinase Inhibitors: Practical Considerations for Nurses and Pharmacists. Nixon S; Duquette D; Doucette S; Larouche JF Curr Oncol; 2023 Apr; 30(4):4222-4245. PubMed ID: 37185435 [TBL] [Abstract][Full Text] [Related]
23. The role of Bruton's kinase inhibitors (BTKi) in accelerated Chronic Lymphocytic Leukemia (a-CLL): a case of successful response to acalabrutinib. Catania G; Tavarozzi R; Pini GM; Borra T; Gandolfo C; Zacchi G; Pietrasanta D; Monaco F; Zanni M; Lettieri M; Rivela P; Zallio F; Ladetto M J Basic Clin Physiol Pharmacol; 2023 May; 34(3):401-404. PubMed ID: 37040263 [TBL] [Abstract][Full Text] [Related]
24. Time-limited, Combined Regimen in Chronic Lymphocytic Leukemia: A Promising Strategy to Achieve a Drug Holiday. Jiang R; Li JY; Zhu HY Curr Med Sci; 2021 Jun; 41(3):431-442. PubMed ID: 34181208 [TBL] [Abstract][Full Text] [Related]
25. New Treatment Options for Newly-Diagnosed and Relapsed Chronic Lymphocytic Leukemia. Iskierka-Jażdżewska E; Obracaj A; Urbaniak M; Robak T Curr Treat Options Oncol; 2022 Jun; 23(6):775-795. PubMed ID: 35357653 [TBL] [Abstract][Full Text] [Related]
26. Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia. Barrientos J; Rai K Leuk Lymphoma; 2013 Aug; 54(8):1817-20. PubMed ID: 23617325 [TBL] [Abstract][Full Text] [Related]
27. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Wiestner A Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631 [TBL] [Abstract][Full Text] [Related]
28. Predictive role of NKCD56bright cells in monitoring the progression of chronic lymphocytic leukemia during treatment. Blachnio K; Grygalewicz B; Woroniecka R; Rygier J; Pienkowska-Grela B; Rymkiewicz G; Kawiak J Folia Histochem Cytobiol; 2022; 60(3):203-214. PubMed ID: 36045602 [TBL] [Abstract][Full Text] [Related]
29. Emergence of Bruton's tyrosine kinase-negative Hodgkin lymphoma during ibrutinib treatment of chronic lymphocytic leukaemia. Glavey S; Quinn J; McCloy M; Sargent J; McCartney Y; Catherwood M; Marafioti T; Leader M; Murphy P; Thornton P Eur J Haematol; 2017 Oct; 99(4):378-380. PubMed ID: 28561533 [TBL] [Abstract][Full Text] [Related]
30. Ibrutinib treatment of CLL: the cancer fights back. Young RM; Staudt LM Cancer Cell; 2014 Jul; 26(1):11-3. PubMed ID: 25026208 [TBL] [Abstract][Full Text] [Related]
31. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies. Aw A; Brown JR Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906 [TBL] [Abstract][Full Text] [Related]
32. Bruton's tyrosine kinase inhibitor restrains Wnt signaling in chronic lymphocytic leukemia. Li PP; Lu K; Geng LY; Zhou XX; Li XY; Wang X Mol Med Rep; 2016 Jun; 13(6):4934-8. PubMed ID: 27082823 [TBL] [Abstract][Full Text] [Related]
33. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition. Dias AL; Jain D Cardiovasc Hematol Agents Med Chem; 2013 Dec; 11(4):265-71. PubMed ID: 24433470 [TBL] [Abstract][Full Text] [Related]
34. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. Xu W; Yang S; Zhou K; Pan L; Li Z; Zhou J; Gao S; Zhou D; Hu J; Feng R; Huang H; Ji M; Guo H; Huang J; Novotny W; Feng S; Li J J Hematol Oncol; 2020 May; 13(1):48. PubMed ID: 32393328 [TBL] [Abstract][Full Text] [Related]